Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Goldie–Coldman and bevacizumab beyond disease progression

Nature Reviews Clinical Oncology volume 6, pages 311–312 (2009)Cite this article

Targeted therapies offer new hope in overcoming the challenges encountered with conventional chemotherapy. However, little is known about the precise mechanisms that cause resistance. These issues are discussed in light of data from the BRiTE study, which indicate that the antiangiogenic effects of bevacizumab might persist despite the development of resistance to first-line chemotherapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

    CAS  PubMed  Google Scholar 

  2. Grothey, A. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26, 5326–5334 (2008).

    Article  CAS  Google Scholar 

  3. Mellor, H. R. & Callaghan, R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81, 275–300 (2008).

    Article  CAS  Google Scholar 

  4. Ho, Q. T. & Kuo, C. J. Vascular endothelial growth factor: biology and therapeutic applications. Int. J. Biochem. Cell Biol. 39, 1349–1357 (2007).

    Article  CAS  Google Scholar 

  5. Jain, R. K. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19, 7–16 (2005).

    Google Scholar 

  6. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592–603 (2008).

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Department of Medicine, The University of Pennsylvania School of Medicine, 12 Penn Tower, 3400 Spruce Street, Philadelphia, OA 19104, USA bruce.giantonio@uphs.upenn.edu

Authors and Affiliations

  1. Abramson Cancer Center of the University of Pennsylvania, PA, USA

    Bruce J. Giantonio

Authors
  1. Bruce J. Giantonio
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

B. J. Giantonio declares he is a consultant for Genentech, and is on the speakers bureau for Genentech, Roche and Sanofi–Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giantonio, B. Goldie–Coldman and bevacizumab beyond disease progression. Nat Rev Clin Oncol 6, 311–312 (2009). https://doi.org/10.1038/nrclinonc.2009.66

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.66

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing